Kura Oncology (KURA) Projected to Post Earnings on Wednesday

Kura Oncology (NASDAQ:KURA) is anticipated to issue its quarterly earnings data after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.65) per share and revenue of $57.96 million for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Kura Oncology Stock Up 1.2 %

NASDAQ KURA opened at $8.25 on Monday. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock’s 50 day moving average is $8.30 and its two-hundred day moving average is $14.12. The company has a market capitalization of $641.21 million, a price-to-earnings ratio of -3.49 and a beta of 0.78. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17.

Insider Buying and Selling

In related news, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares in the company, valued at $694,551.11. The trade was a 5.32 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock worth $92,307 in the last quarter. Insiders own 5.50% of the company’s stock.

Analyst Ratings Changes

KURA has been the topic of a number of recent research reports. TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. Bank of America cut their target price on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, November 22nd. BTIG Research cut shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. HC Wainwright lifted their target price on shares of Kura Oncology from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. Finally, Jefferies Financial Group cut their target price on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, November 21st. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $27.13.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.